Liso-Cel Demonstrates “Remarkable” Activity, Lower Toxicity in Patients With DLBCL – Targeted Oncology
Targeted Oncology |
Liso-Cel Demonstrates "Remarkable" Activity, Lower Toxicity in Patients With DLBCL
Targeted Oncology Maloney: JCAR017 is a CAR T-cell product directed against CD19. This is in multicenter clinical trials in aggressive large B-cell lymphoma. The product is different from other CAR T cells since it is a subset population where patients have their cells … |
